Segui
Thierry Buclin
Thierry Buclin
CHUV and UNIL Lausanne (Switzewrland)
Email verificata su chuv.hospvd.ch - Home page
Titolo
Citata da
Citata da
Anno
Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance
C Marzolini, E Paus, T Buclin, RB Kim
Clinical Pharmacology & Therapeutics 75 (1), 13-33, 2004
11862004
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini, A Telenti, LA Decosterd, G Greub, J Biollaz, T Buclin
Aids 15 (1), 71-75, 2001
10722001
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
A Pascual, T Calandra, S Bolay, T Buclin, J Bille, O Marchetti
Clinical infectious diseases 46 (2), 201-211, 2008
9472008
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
J Fellay, C Marzolini, ER Meaden, DJ Back, T Buclin, JP Chave, ...
The Lancet 359 (9300), 30-36, 2002
8042002
Interindividual variability of the clinical pharmacokinetics of methadone
CB Eap, T Buclin, P Baumann
Clinical pharmacokinetics 41 (14), 1153-1193, 2002
6792002
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients
S Ostermann, C Csajka, T Buclin, S Leyvraz, F Lejeune, LA Decosterd, ...
Clinical cancer research 10 (11), 3728-3736, 2004
4772004
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
M Rotger, S Colombo, H Furrer, G Bleiber, T Buclin, BL Lee, O Keiser, ...
Pharmacogenetics and genomics 15 (1), 1-5, 2005
4632005
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients
S Lavoie, MM Murray, P Deppen, MG Knyazeva, M Berk, O Boulat, ...
Neuropsychopharmacology 33 (9), 2187-2199, 2008
4032008
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
C Csajka, C Marzolini, K Fattinger, LA Décosterd, J Fellay, A Telenti, ...
Clinical Pharmacology & Therapeutics 73 (1), 20-30, 2003
3282003
Towards a new combination therapy for tuberculosis with next generation benzothiazinones
V Makarov, B Lechartier, M Zhang, J Neres, AM van der Sar, SA Raadsen, ...
EMBO molecular medicine 6 (3), 372-383, 2014
3012014
Diet acids and alkalis influence calcium retention in bone
T Buclin, M Cosma, M Appenzeller, AF Jacquet, LA Decosterd, J Biollaz, ...
Osteoporosis International 12 (6), 493-499, 2001
2832001
Antidepressants for the treatment of chronic pain
B Verdu, I Decosterd, T Buclin, F Stiefel, A Berney
Drugs 68 (18), 2611-2632, 2008
2612008
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
A Haouala, N Widmer, MA Duchosal, M Montemurro, T Buclin, ...
Blood, The Journal of the American Society of Hematology 117 (8), e75-e87, 2011
2432011
Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics–based analysis of adult patients with invasive …
A Pascual, C Csajka, T Buclin, S Bolay, J Bille, T Calandra, O Marchetti
Clinical infectious diseases 55 (3), 381-390, 2012
2102012
Population pharmacokinetics of imatinib and the role of α1‐acid glycoprotein
N Widmer, LA Decosterd, C Csajka, S Leyvraz, MA Duchosal, A Rosselet, ...
British journal of clinical pharmacology 62 (1), 97-112, 2006
1952006
The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial
C Mazzocato, T Buclin, CH Rapin
Annals of oncology 10 (12), 1511-1514, 1999
1861999
Benchmarking therapeutic drug monitoring software: a review of available computer tools
A Fuchs, C Csajka, Y Thoma, T Buclin, N Widmer
Clinical pharmacokinetics 52 (1), 9-22, 2013
1532013
Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists
C Csajka, T Buclin, HR Brunner, J Biollaz
Clinical pharmacokinetics 32 (1), 1-29, 1997
1531997
Pharmacogenetics‐based population pharmacokinetic analysis of efavirenz in HIV‐1‐infected individuals
M Arab‐Alameddine, J Di Iulio, T Buclin, M Rotger, R Lubomirov, ...
Clinical Pharmacology & Therapeutics 85 (5), 485-494, 2009
1522009
High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function
F Lamoth, T Buclin, A Pascual, S Vora, S Bolay, LA Decosterd, T Calandra, ...
Antimicrobial agents and chemotherapy 54 (10), 4360-4367, 2010
1512010
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20